Ignite Creation Date:
2024-05-06 @ 7:43 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02581176
Status:
COMPLETED
Last Update Posted:
2018-06-26
First Post:
2015-10-19
Brief Title:
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer The CAP Study
Sponsor:
University Hospital Akershus
Organization:
University Hospital Akershus
Study Overview
Official Title:
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer The CAP Study
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAP
Brief Summary:
This study is a single-arm phase IV trial of apixaban as treatment of venous thrombosis in patients with cancer The current standard treatment of venous thrombosis in cancer patients is subcutaneous injections with low molecular weight heparin During the last 5 years several new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis But very few cancer patients were included in the phase III clinical trials of the direct acting oral anticoagulants Thus there is a lack of information on how cancer patients with venous thrombosis will respond to treatment with direct acting oral anticoagulants The current study will investigate the direct acting oral anticoagulant apixaban in cancer patients with venous thrombosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None